港股異動 | 中國利郎(1234.HK)續漲逾6% 品牌銷量增加疊加機構看好
格隆匯10月14日丨中國利郎(1234.HK)延續近期強勢,現報5.2港元,漲幅6.12%,最新總市值62.3億港元,近四個交易日累計漲逾20%。公司12日公告稱,第三季度“LILANZ”產品的零售金額(按零售價值計算)與2019年同期比較上升5%至10%。廣發證券指,公司品牌利郎增長超預期。公司預期下半年零售金額同比增長不低於5%,考慮到第三季度超預期,且近期全國大範圍降温,冬裝銷售旺季有望提前到來,公司現貨補貨有望增加進而帶動公司業績增長。維持“買入”評級,目標價6.25港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.